BioCardia, Inc. Increase (Decrease) in Accrued Liabilities
BioCardia, Inc. (BCDA) reported Increase (Decrease) in Accrued Liabilities of $797.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2021-03-30
- BioCardia, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-06-30 was $530.00K, a 4.33% increase year-over-year.
- BioCardia, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-03-31 was $293.00K.
- BioCardia, Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-06-30 was $508.00K.
- BioCardia, Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-03-31 was -$36.00K, a 205.88% decline year-over-year.
- BioCardia, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $797.00K, a 13.56% decline from fiscal 2019.
- BioCardia, Inc. increase (decrease) in accrued liabilities for fiscal 2019 was $922.00K, a 284.17% increase from fiscal 2018.
- BioCardia, Inc. increase (decrease) in accrued liabilities for fiscal 2018 was $240.00K, a 42.17% decline from fiscal 2017.
- BioCardia, Inc. increase (decrease) in accrued liabilities for fiscal 2017 was $415.00K, a 21.70% decline from fiscal 2016.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $797.00K 10-K · filed 2021-03-30 | |||||
| 2020-06-30 | $530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $823.00K 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $293.00K 10-Q · filed 2020-05-15 | |||||
| 2019-12-31 | $922.00K 10-K · filed 2021-03-30 | |||||
| 2019-06-30 | $508.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $472.00K 10-Q · filed 2020-08-13 | $571.00K derived: sum of 3 quarters · filed 2020-08-13 | $687.00K derived: sum of 4 quarters · filed 2020-08-13 | ||
| 2019-03-31 | -$36.00K 10-Q · filed 2020-05-15 | $63.00K derived: sum of 2 quarters · filed 2020-05-15 | $179.00K derived: sum of 3 quarters · filed 2020-05-15 | $170.00K derived: sum of 4 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $215.00K derived: sum of 2 quarters · filed 2020-04-09 | $206.00K derived: sum of 3 quarters · filed 2020-04-09 | $240.00K 10-K · filed 2020-04-09 | ||
| 2018-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $107.00K derived: sum of 2 quarters · filed 2018-11-08 | $141.00K 10-Q · filed 2018-11-08 | $11.00K derived: sum of 4 quarters · filed 2020-04-09 | ||
| 2018-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $25.00K 10-Q · filed 2018-08-09 | -$105.00K derived: sum of 3 quarters · filed 2020-04-09 | $424.00K derived: sum of 4 quarters · filed 2020-04-09 | ||
| 2018-03-31 | $34.00K 10-Q · filed 2018-05-10 | -$96.00K derived: sum of 2 quarters · filed 2020-04-09 | $433.00K derived: sum of 3 quarters · filed 2020-04-09 | $292.00K derived: sum of 4 quarters · filed 2020-04-09 | ||
| 2017-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | $399.00K derived: sum of 2 quarters · filed 2020-04-09 | $258.00K derived: sum of 3 quarters · filed 2020-04-09 | $415.00K 10-K · filed 2020-04-09 | ||
| 2017-09-30 | $529.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $388.00K derived: sum of 2 quarters · filed 2018-11-08 | $545.00K 10-Q · filed 2018-11-08 | $840.00K derived: sum of 4 quarters · filed 2019-04-02 | ||
| 2017-06-30 | -$141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $16.00K 10-Q · filed 2018-08-09 | $311.00K derived: sum of 3 quarters · filed 2019-04-02 | |||
| 2017-03-31 | $157.00K 10-Q · filed 2018-05-10 | $176.00K 10-Q · filed 2017-05-11 | $452.00K derived: sum of 2 quarters · filed 2019-04-02 | |||
| 2016-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $530.00K 10-K · filed 2019-04-02 | $226.00K 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $235.00K 10-Q · filed 2017-11-09 | |||||
| 2016-03-31 | $86.00K 10-Q · filed 2017-05-11 | |||||
| 2015-12-31 | -$416.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |